Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | CA4 | P22748 | 6/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PTGIR | P43119 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347947 | 0.85 | PPARA (0.44) | PPARAPPARGLMNAPLA2G4B | |
| SCHEMBL19501291 | 0.85 | PPARA (0.48) | PPARAPPARGLMNAFFAR1CA12 | |
| SCHEMBL1662603 | 0.85 | PPARG (0.44) | PPARAPPARGLMNACA12CA1 | |
| SCHEMBL7049768 | 0.84 | LMNA (0.62) | PPARAPPARGLMNAALOX15PTPN7 | |
| SCHEMBL4465276 | 0.84 | LMNA (0.62) | PPARAPPARGLMNAALOX15PTPN7 | |
| SCHEMBL413254 | 0.83 | LMNA (0.81) | PPARAPPARGLMNAALOX15PTPN7 | |
| SCHEMBL1910457 | 0.83 | PPARA (0.60) | PPARAPPARGLMNAALOX15PTPN7 | |
| SCHEMBL9791647 | 0.83 | PPARA (0.60) | PPARAPPARGLMNAALOX15PTPN7 | |
| SCHEMBL29403718 | 0.83 | PPARA (0.60) | PPARAPPARGLMNAALOX15PTPN7 | |
| SCHEMBL2936246 | 0.83 | PPARA (0.60) | PPARAPPARGLMNAALOX15PTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0434034-A1 | Oxazole derivatives | Bristol-Myers Squibb Company (US) | 1991-06-26 | — | — | EP | claimed |
| EP-2733534-B1 | COMPOSITION FOR FORMING FINE PATTERN AND METHOD FOR FORMING FINED PATTERN USING SAME | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9298094-B2 | Composition for forming fine pattern and method for forming fined pattern using same | MERCK PATENT GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9298094-B2 | Composition for forming fine pattern and method for forming fined pattern using same | MERCK PATENT GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| EP-2733534-A1 | COMPOSITION FOR FORMING FINE PATTERN AND METHOD FOR FORMING FINED PATTERN USING SAME | AZ Electronic Materials USA Corp. (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140127478-A1 | COMPOSITION FOR FORMING FINE PATTERN AND METHOD FOR FORMING FINED PATTERN USING SAME | AZ ELECTRONIC MATERIALS USA CORP. | 2014-05-08 | — | — | US | disclosed |
| US-20140127478-A1 | COMPOSITION FOR FORMING FINE PATTERN AND METHOD FOR FORMING FINED PATTERN USING SAME | AZ ELECTRONIC MATERIALS USA CORP. | 2014-05-08 | — | — | US | disclosed |
| EP-1719768-B1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| CN-102293773-A | Drug with benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORP | 2011-12-28 | — | — | CN | disclosed |
| EP-1283825-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | Novartis AG (CH) | 2003-02-19 | — | — | EP | disclosed |
| EP-1000038-B1 | NOVEL PYRIMIDIN DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002056885-A1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6350756-B1 | USEFUL FOR TREATING CANCER; (20S) ESTERS WITH AN OXYALKANOIC ACID; | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-02-26 | — | — | US | disclosed |
| WO-2001087828-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2001-11-22 | — | — | WO | disclosed |
| US-6200981-B1 | FOR TREATING INFLAMMATORY DISEASES SUCH AS ASTHMA, INFLAMMATORY BOWEL DISEASE, PSORIASIS, RHEUMATOID ARTHRITIS, MYOCARDIAL ISCHAEMIA, CYSTIC FIBROSIS, ARTHEREOSCLEROSIS, RESTENOSIS, PERIDONTAL DISEASE, SEPTIC SHOCK, OSTEOARTHRITIS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1000038-A1 | NOVEL PYRIMIDIN DERIVATIVES | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005123-A1 | NOVEL PYRIMIDIN DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
| US-5262540-A | FOR INHIBITION OF BLOOD PLATELET AGGREGATION IN MAMMALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0434034-A1 | Oxazole derivatives | Bristol-Myers Squibb Company (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | PPARA 90/4885PPARG 268/4885LMNA 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.